<?xml version="1.0" encoding="UTF-8"?>
<p>Combating and controlling NIDs is therefore a global challenge, but a number of scientific and commercial obstacles impede the development of new medical products. Of the 850 new therapeutic products registered between 2000 and 2011, only 18 (2%) were indicated for NIDs 
 <xref rid="bb0015" ref-type="bibr">[3]</xref>. As a result, patients with NIDs are often treated with antiquated drugs that are ineffective, toxic or difficult to administer, while for some NIDs such as Buruli ulcer no drugs or vaccines of any kind are available.
</p>
